Latest News and Press Releases
Want to stay updated on the latest news?
-
OKI-179 demonstrated chemical synthetic lethality when combined with MEK and BRAF inhibitors in RAS pathway mutated cancer models The Company plans to initiate the OKI-179-230 Phase 1b/2 trial of...
-
BOULDER, Colo., March 08, 2022 (GLOBE NEWSWIRE) -- OnKure, Inc., a clinical-stage biopharmaceutical company discovering and developing the next generation of oncology precision medicines, today...
-
BOULDER, Colo., Feb. 08, 2022 (GLOBE NEWSWIRE) -- OnKure, Inc., a clinical-stage biopharmaceutical company discovering and developing the next generation of oncology precision medicines, today...